Terms: = Endocrine gland cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Clinical Outcome
52 results:
1. Predictive and prognostic biomarkers in urological tumours.
Cimadamore A; Franzese C; Di Loreto C; Blanca A; Lopez-Beltran A; Crestani A; Giannarini G; Tan PH; Carneiro BA; El-Deiry WS; Montironi R; Cheng L
Pathology; 2024 Mar; 56(2):228-238. PubMed ID: 38199927
[TBL] [Abstract] [Full Text] [Related]
2. clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in brca1 and BRCA2 genes.
Militello AM; Orsi G; Cavaliere A; Niger M; Avallone A; Salvatore L; Tortora G; Rapposelli IG; Giordano G; Noventa S; Giommoni E; Bozzarelli S; Macchini M; Peretti U; Procaccio L; Puccini A; Cascinu S; Montagna C; Milella M; Reni M
Cancer Chemother Pharmacol; 2023 Dec; 92(6):501-510. PubMed ID: 37725113
[TBL] [Abstract] [Full Text] [Related]
3. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract] [Full Text] [Related]
4. Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with brca1 c.5096G>A (R1699Q) intermediate-risk variant.
Saito A; Tanioka M; Hirata M; Watanabe T; Odaka Y; Shimoi T; Sudo K; Noguchi E; Ishikawa M; Yonemori K
Cancer Treat Res Commun; 2022; 32():100587. PubMed ID: 35696850
[TBL] [Abstract] [Full Text] [Related]
5.
Liontos M; Zografos E; Zoumpourlis P; Andrikopoulou A; Svarna A; Fiste O; Kunadis E; Papatheodoridi AM; Kaparelou M; Koutsoukos K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
Curr Oncol; 2021 Nov; 28(6):4446-4456. PubMed ID: 34898566
[TBL] [Abstract] [Full Text] [Related]
6. brca1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer.
Elazezy M; Prieske K; Kluwe L; Oliveira-Ferrer L; Peine S; Müller V; Woelber L; Schmalfeldt B; Pantel K; Joosse SA
Mol Oncol; 2021 Dec; 15(12):3615-3625. PubMed ID: 34601813
[TBL] [Abstract] [Full Text] [Related]
7. clinical outcome in patients with primary epithelial ovarian cancer and germline brca1/2-mutation - real life data.
Ataseven B; Tripon D; Schwameis R; Harter P; Rhiem K; Schneider S; Heikaus S; Baert T; Francesco AP; Heitz F; Traut A; Groeben HT; Schmutzler R; du Bois A
Gynecol Oncol; 2021 Dec; 163(3):569-577. PubMed ID: 34565600
[TBL] [Abstract] [Full Text] [Related]
8. Improving Gemcitabine Sensitivity in Pancreatic cancer Cells by Restoring miRNA-217 Levels.
Panebianco C; Trivieri N; Villani A; Terracciano F; Latiano TP; Potenza A; Perri F; Binda E; Pazienza V
Biomolecules; 2021 Apr; 11(5):. PubMed ID: 33925948
[TBL] [Abstract] [Full Text] [Related]
9. Nomogram-Based Preoperative Score for Predicting clinical outcome in Unilateral Primary Aldosteronism.
Yang Y; Williams TA; Song Y; Yang S; He W; Wang K; Cheng Q; Ma L; Luo T; Yang J; Reincke M; Burrello J; Li Q; Mulatero P; Hu J
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32898224
[TBL] [Abstract] [Full Text] [Related]
10. Germline and Somatic brca1/2 Gene Mutational Status and clinical outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube cancer: Over a Decade of Experience in a Single Institution in Korea.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
[TBL] [Abstract] [Full Text] [Related]
11. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
Matsushita H; Hasegawa K; Oda K; Yamamoto S; Asada K; Karasaki T; Yabuno A; Nishijima A; Nejo T; Kobayashi Y; Sato S; Ikeda Y; Miyai M; Takahashi Y; Yamaguchi R; Fujiwara K; Aburatani H; Kakimi K
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461346
[TBL] [Abstract] [Full Text] [Related]
12. In silico analysis of DYNLL1 expression in ovarian cancer chemoresistance.
Berkel C; Cacan E
Cell Biol Int; 2020 Aug; 44(8):1598-1605. PubMed ID: 32208526
[TBL] [Abstract] [Full Text] [Related]
13. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and brca1/2 gene mutational status.
Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
[TBL] [Abstract] [Full Text] [Related]
14. Identification of immune-enhanced molecular subtype associated with brca1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma.
Zheng M; Hu Y; Gou R; Liu O; Nie X; Li X; Liu Q; Hao Y; Liu J; Lin B
J Cell Mol Med; 2020 Mar; 24(5):2819-2831. PubMed ID: 31995855
[TBL] [Abstract] [Full Text] [Related]
15. A nomogram for individualized estimation of survival among adult patients with adrenocortical carcinoma after surgery: a retrospective analysis and multicenter validation study.
Kong J; Zheng J; Cai J; Wu S; Diao X; Xie W; Chen X; Liao C; Yu H; Fan X; Huang C; Liu Z; Chen W; Lv Q; Qin H; Huang J; Lin T
Cancer Commun (Lond); 2019 Nov; 39(1):80. PubMed ID: 31775884
[TBL] [Abstract] [Full Text] [Related]
16. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract] [Full Text] [Related]
17. clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse.
Hollis RL; Carmichael J; Meynert AM; Churchman M; Hallas-Potts A; Rye T; MacKean M; Nussey F; Semple CA; Herrington CS; Gourley C
Am J Obstet Gynecol; 2019 Sep; 221(3):245.e1-245.e15. PubMed ID: 31055034
[TBL] [Abstract] [Full Text] [Related]
18. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract] [Full Text] [Related]
19. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract] [Full Text] [Related]
20. Immunogenomic Analyses of Advanced Serous Ovarian cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
Hao D; Liu J; Chen M; Li J; Wang L; Li X; Zhao Q; Di LJ
Clin Cancer Res; 2018 Aug; 24(15):3560-3571. PubMed ID: 29661778
[No Abstract] [Full Text] [Related]
[Next]